Pharmaceuticals & Therapeutics

A new partnership brings prescription pain patches directly to consumers online, signaling a major shift in how patients access affordable generic medicines.

AVEO Oncology's ficlatuzumab advances in a pivotal Phase 3 trial, offering new hope for patients with a difficult-to-treat form of head and neck cancer.

Bausch + Lomb beats Q4 revenue forecasts, propelled by its blockbuster dry eye drug MIEBO, and issues a confident financial outlook for 2026.

Positive early trial data for ZP9830 shows promise for a new class of targeted autoimmune therapies, marking a strategic pivot for Zealand Pharma.

Amid market volatility, the S&P 500 firm reinforces its financial strength with a massive share repurchase program and its 34th year of dividend growth.

With strong growth and a high valuation, BrightSpring's upcoming Investor Day is a key moment to outline its strategy for profitability and market leadership.

Genmab posts record 2025 revenue, driven by cancer drug sales and a major acquisition, setting an ambitious, investment-heavy course for 2026.

United Vein & Vascular Centers opens its sixth Phoenix-area clinic in Mesa, bringing minimally invasive treatments to a region with growing healthcare needs.

As Adagene presents at key conferences, its SAFEbody tech and lead drug muzastotug draw focus amid a strategic push for funding and partnerships.

Utah's fast-growing wellness brand launches 15 bestsellers nationwide, signaling a major shift toward ingredient transparency in mass-market retail.

Accord Healthcare's launch of generic lenalidomide signals a new era of affordability for a key cancer drug, intensifying competition and lowering costs.

Annexon Biosciences spotlights its novel C1q inhibitor, Vonaprument, aiming to be the first therapy to preserve vision in geographic atrophy patients.

A new oral drug from Nimbus Therapeutics uses AI-driven precision to fight inflammation and repair tissue, offering new hope for millions with IBD.

Cyrano Therapeutics' CYR-064 shows promise in a Phase 2 study, potentially becoming the first approved drug for persistent post-viral smell loss.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

At a key conference, DocGo's CEO will navigate financial headwinds while promoting a vision for proactive, tech-enabled healthcare delivery.

A new FDA approval allows a lung cancer therapy to be given just once a month, a major shift promising to reduce clinic time and improve quality of life.

With its burn treatment gaining traction and a pivotal wound care drug in late-stage trials, MediWound prepares to make its case to Wall Street.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.